Chinese biopharmaceutical company: TQB2868 combination therapy shows breakthrough efficacy in pancreatic cancer treatment.

The Chinese biopharmaceutical company announced that at the 2025 American Society of Clinical Oncology Annual Meeting, the Group presented preliminary data from a Phase II clinical study of TQB2868, a PD-1/TGF- dual-function fusion protein, in combination with Anlotinib and first-line chemotherapy for metastatic pancreatic ductal adenocarcinoma (mPDAC). As of January 2025, the study has enrolled 40 patients with mPDAC, of which 36 are evaluable. Preliminary data shows that the objective response rate of TQB2868 in combination with Anlotinib and AG chemotherapy is 63.9%, 2-3 times higher than historical data of AG chemotherapy; the disease control rate is 100%, 1.6 times higher than AG chemotherapy; the median progression-free survival has not been reached, with a 6-month PFS rate of 86%, which is double that of AG chemotherapy; the median overall survival has not been reached, and is expected to exceed one year. In terms of safety, the combination of TQB2868 is well tolerated, with a rate of grade 3 or higher adverse reactions of 52.5%. The Group is currently in communication with the National Medical Products Administration Drug Evaluation Center regarding the registration of a Phase III clinical trial for the TQB2868 combination regimen.